Allogene Therapeutics Inc [NASDAQ: ALLO] closed the trading session at $1.29 on 2025-07-30. The day’s price range saw the stock hit a low of $1.265, while the highest price level was $1.49.
The stocks have a year to date performance of -57.00 percent and weekly performance of -22.29 percent. The stock has been moved at -33.16 percent over the last six months. The stock has performed 14.16 percent around the most recent 30 days and changed -16.23 percent over the most recent 3-months.
If compared to the average trading volume of 3.42M shares, ALLO reached to a volume of 9250031 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Allogene Therapeutics Inc [ALLO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ALLO shares is $8.05 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALLO stock is a recommendation set at 1.36. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citizens JMP have made an estimate for Allogene Therapeutics Inc shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on May 14, 2025. The new note on the price target was released on March 14, 2025, representing the official price target for Allogene Therapeutics Inc stock. Previously, the target price had yet another drop from $13 to $11, while Oppenheimer kept a Outperform rating on ALLO stock.
The Price to Book ratio for the last quarter was 0.73, with the Price to Cash per share for the same quarter was set at 1.28.
ALLO stock trade performance evaluation
Allogene Therapeutics Inc [ALLO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -22.29. With this latest performance, ALLO shares gained by 14.16% in over the last four-week period, additionally sinking by -33.16% over the last 6 months – not to mention a drop of -39.44% in the past year of trading.
Allogene Therapeutics Inc (ALLO) Capital Structure & Debt Analysis
According to recent financial data for Allogene Therapeutics Inc. ( ALLO), the Return on Equity (ROE) stands at -59.60%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -46.11%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Allogene Therapeutics Inc’s Return on Invested Capital (ROIC) is -54.07%, showcasing its effectiveness in deploying capital for earnings.
Allogene Therapeutics Inc (ALLO) Efficiency & Liquidity Metrics
Based on Allogene Therapeutics Inc’s (ALLO) latest financial statements, the Debt-to-Equity Ratio is 0.23%, indicating its reliance on debt financing relative to shareholder equity.
Allogene Therapeutics Inc (ALLO) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Allogene Therapeutics Inc. (ALLO) effectively leverages its workforce, generating an average of -$1101834.06 per employee. The company’s liquidity position is robust, with a Current Ratio of 9.71% and a Quick Ratio of 9.71%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Allogene Therapeutics Inc [ALLO] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALLO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Allogene Therapeutics Inc go to 8.47%.
Allogene Therapeutics Inc [ALLO]: Institutional Ownership
There are presently around $81.78%, or 99.36% of ALLO stock, in the hands of institutional investors. The top three institutional holders of ALLO stocks are: FMR LLC with ownership of 31.26 million shares, which is approximately 16.4491%. TPG GP A, LLC, holding 18.72 million shares of the stock with an approximate value of $$43.61 million in ALLO stocks shares; and TPG GP A, LLC, currently with $$38.32 million in ALLO stock with ownership which is approximately 8.6544%.
